Recent landmark trials showed a huge improvement in progression-free survival of crizotinib-treated patients with anaplastic lymphoma kinase (ALK) translocation, metastatic non-small-cell lung cancer (NSCLC) and thereafter changed the treatment of this disease [36, 37]. Here, ALK is linked to non-small cell lung carcinoma.